WASHINGTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Society for Science today announced the 30 finalists in the Thermo Fisher Scientific Junior Innovators Challenge (Thermo Fisher JIC), the nation’s premier middle school science, technology, engineering and mathematics (STEM) competition. The finalists — selected by a nationwide panel of scientists, engineers and educators from the Top 300 Junior Innovators announced earlier this month — will participate in Thermo Fisher JIC Finals Week (Oct. 24–29) in Washingto ...

We came across a bullish thesis on Bruker Corporation on Value investing subreddit by AvocadoCorrect9725. In this article, we will summarize the bulls’ thesis on BRKR. Bruker Corporation's share was trading at $29.79 as of September 4th. BRKR’s trailing and forward P/E were 57.29 and 11.82 respectively according to Yahoo Finance. 5 Highest Paying Countries for Neurosurgeons sfam_photo/Shutterstock.com Bruker Corporation (BRKR) appears to have experienced an overly negative market reaction following its ...

With a market cap of $35.2 billion, Agilent Technologies, Inc. (A) is a leading global provider of application-focused solutions for the life sciences, diagnostics, and applied chemical markets. The company operates through three core segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab, offering a diverse portfolio of instruments, consumables, software, and services. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Agilent ...

摘要 ： 色谱工作者检查和诊断色谱分析鬼峰时，需要注意实验场所空气和顶空耗材等导致的污染，需要注意顶空耗材的选购和保 存问题。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 案例情况简介 某药物生产企业质检部门使用 Shimadzu 公司 气相色谱仪 GC-2030 与 HS-20 顶空进样器，测定某药品中溶剂残 留。进样时发现谱图中存在较多鬼峰，分析条件如表 1 所示，鬼峰情况如图 1 所示。 按照一般检查鬼峰的原则，首先运行一下程序升温空白，考察鬼峰是否来自 气相色谱仪 本身。 将工作站的系统配置中 HS-20 删除，执行单次进样指令，系统不进样任何样品，运行程序升温并采集数据，考察此 时数据，无明显鬼峰出现。那么就可以排除 气相色谱仪 污染的可能性。 然后考察实验室空气。将色谱柱安装至 气相色谱 的液体进样口，找 1mL 气密性注射器，吸取实验室和配样实验室的 空气，进样 0.8mL ，采集数据。观察此数据中无明显鬼峰。 用户自行使用高温水蒸气清洗的方法处理顶空进样器未能奏效，谱图鬼峰未见改善。询问用户处理方法，用户自述顶空 瓶中装 ...

Core Insights - Agilent Technologies' international operations are crucial for understanding its financial resilience and growth potential [1][2] - The company's reliance on foreign markets is essential for consistent earnings and navigating different economic cycles [2][3] Revenue Performance - Total revenue for the recent quarter reached $1.74 billion, reflecting a 10.1% increase from the prior-year quarter [4] - Asia Pacific contributed $563 million, accounting for 32.4% of total revenue, but showed a decline of -1.9% compared to analyst expectations [5] - Europe generated $492 million, representing 28.3% of total revenue, with a positive surprise of +16.47% compared to projections [6] Future Revenue Expectations - Analysts predict total revenue of $1.83 billion for the current fiscal quarter, indicating a 7.8% increase year-over-year [7] - For the full year, total revenue is expected to reach $6.86 billion, up 5.4% from the previous year, with Asia Pacific and Europe projected to contribute $2.29 billion and $1.77 billion, respectively [8] Market Dynamics - The company's international revenue trends present both opportunities and challenges, necessitating close monitoring for future projections [9] - Global interconnections and geopolitical issues are increasingly influencing earnings predictions for companies with overseas operations [10] Stock Performance - Agilent's stock has increased by 10.7% over the past month, outperforming the S&P 500's 1.6% increase [13] - Over the past three months, the company's shares rose by 8.5%, while the S&P 500 increased by 9.7% [13]

Financial Data and Key Metrics Changes - The company reported revenue of $1,740 million in Q3 2025, exceeding guidance, with earnings per share of $1.37, marking a 4% year-over-year increase [5][32] - Core revenue growth was 6.1%, with reported growth at 10.1%, benefiting from favorable currency impacts of 2.1% and M&A contributions of 1.9% [28][29] - Gross margins were 53.1%, down year-over-year due to tariffs, currency effects, and downtime related to capacity expansion [29][30] Business Line Data and Key Metrics Changes - The pharma segment grew 9%, with small molecule growth in double digits driven by demand in QAQC and adoption of the Infinity Tree LC platform [16][17] - Chemical and Advanced Materials saw a 10% growth, supported by capital investments and demand in semiconductor and chemical sectors [17][20] - The Life Sciences and Diagnostics market grew 7%, with strong performance in LC and LC MS instruments [18][19] Market Data and Key Metrics Changes - Demand outside The Americas grew in the low 30s, with significant contributions from Asia ex China and EMEA [10][22] - The U.S. market faced challenges, particularly in biopharma spending, but small molecule pharma and chemicals showed low double-digit growth [24][25] - Environmental and Forensics markets declined due to changes in U.S. EPA regulations, impacting capital spending [9][24] Company Strategy and Development Direction - The company is focused on its Ignite enterprise operating model, which aims to streamline operations and enhance decision-making speed [10][12] - Innovation remains a key driver, with new product launches like the Infinity Tree LC platform and Pro IQ LC MS system expected to support sustained growth [13][14] - The company is raising its full-year revenue guidance to $6,910 million to $6,930 million, reflecting confidence in continued momentum [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating tariff impacts by 2026 and highlighted the importance of capital investments in driving future growth [12][30] - The company anticipates Q4 to be its largest revenue quarter of the year, with core growth of 5.4% [14][36] - Management noted that customer budgets are normalizing, leading to larger quotes and improved spending visibility in the pharma sector [50][70] Other Important Information - The company has streamlined its management structure, reducing layers by over 15%, which has contributed to operational efficiency [10][12] - Tariff expenses were higher than expected, with a projected net cost of $20 million for the year due to increased shipment volumes and inventory [38][39] Q&A Session Summary Question: Can you unpack the margin variables? - Management indicated that higher tariffs, increased variable pay, and incremental commercial investments were the main factors affecting margins [42][44] Question: What is the outlook for NASD growth? - NASD is expected to continue strong momentum, with high single-digit to double-digit growth anticipated [52][53] Question: How widespread is the reduced dependency on sign-offs? - This trend is noted across all geographies, particularly in small molecule and large pharma, improving momentum in customer spending [56][57] Question: What is the impact of tariffs on customer buying behavior? - Management reported no significant pull forwards or stocking behaviors, with strong lab activity supporting demand [90][93] Question: What are the expectations for 2026? - Management is optimistic about 2026, expecting continued growth driven by strong demand and successful mitigation of tariff impacts [66][104]

Core Insights - Suzhou Yilit Technology Co., Ltd. has established itself as a leading enterprise in the domestic liquid chromatography sector, with over 30 years of industry experience and more than 100 technology patents [1][3] - The company has developed China's first commercial chromatography column and the first commercial liquid chromatography instrument, showcasing its commitment to independent research and development [3] - Yilit's core technology team consists of over 50 professionals, achieving a 98% localization rate for key components of its chromatography equipment, with some products meeting international advanced standards [3] Group 1 - The establishment of the Science and Technology Association (STA) at Yilit marks a significant milestone, with the total number of enterprise STAs in Gusu District reaching 25 and registered technology workers exceeding 1,000 [1] - Yilit's recent achievements include the launch of the Rubikstation network version chromatography data workstation and recognition as a "unicorn" cultivation enterprise for 2024 in Suzhou [3] - The company aims to leverage the advantages of the STA to focus on technological breakthroughs and ecosystem development, promoting the upgrade of domestic scientific instruments towards high precision, reliability, and intelligence [3] Group 2 - The Gusu District enterprise STA has been actively involved in talent cultivation, independent innovation, scientific research, academic exchanges, and technology training, contributing to accelerated enterprise development [5] - The district's STA plans to enhance organizational coverage and resource integration, aiming to stimulate innovation potential among scientific and technological talents [5] - The initiative is expected to inject new vitality into the high-quality development of the ancient city [5]

Core Viewpoint - Shanghai has introduced nine significant measures to support enterprises in enhancing basic research, aiming to boost high-quality development and strengthen the role of enterprises in technological innovation [2][4]. Group 1: Financial Support Measures - Enterprises using large scientific instruments will receive a 50% subsidy on expenses, with a maximum annual reimbursement of 1 million yuan [2][4]. - Financial support for enterprises increasing basic research investment includes one-time subsidies of 10 million yuan for those investing over 100 million yuan annually, 5 million yuan for investments between 50 million and 100 million yuan, and 2 million yuan for investments between 10 million and 50 million yuan [4][5]. - Enterprises establishing public welfare funds for basic research will receive support equal to 50% of the fund's contributions towards research projects [4][5]. Group 2: Collaborative and Strategic Initiatives - The measures encourage enterprises to participate in decision-making for basic research, enhancing the involvement of business leaders and strategic investors [4]. - The "Explorer Program" will be implemented to support enterprises focusing on urgent scientific issues, particularly in key industries like integrated circuits, biomedicine, and artificial intelligence [4][5]. - Collaboration between enterprises and universities will be promoted through the establishment of innovation centers, with joint funding from both sectors [4][5]. Group 3: Tax Incentives and Evaluation - Enterprises supporting non-profit research institutions and universities can deduct their contributions from taxable income, with a 100% pre-tax deduction available [4][5]. - A robust evaluation system will be established for enterprises involved in key laboratory projects, ensuring that basic research investment constitutes at least 10% of total R&D spending [5]. Group 4: Monitoring and Reporting - The government will enhance tracking and monitoring of enterprise basic research activities, guiding the establishment of statistical records [5]. - Recognition and encouragement will be given to enterprises achieving significant results in basic research [5].

Financial Data and Key Metrics Changes - Sales grew 9% as reported and 8% in constant currency, with non-GAAP earnings per share at $2.95, up 12% year on year [9][10][21] - GAAP EPS was $2.47, with gross margin at 58.3% and adjusted operating margin at 29.1% [21][24] - Free cash flow was $159 million after funding $23 million of capital expenditures, with a net debt position of $1.1 billion at the end of the quarter [22][24] Business Line Data and Key Metrics Changes - Instruments grew mid-single digits, led by high single-digit growth in the LC and mass spec portfolio [9][10] - Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth [10][21] - Chemistry benefited from approximately $8 million of sales pull forward related to tariff dynamics, with overall constant currency growth rate at 7% and chemistry up 10% [11][21] Market Data and Key Metrics Changes - By end market, pharma grew low double digits, industrial grew 6%, and academic and government declined low single digits [11][17] - In the Americas, growth was partially offset by weakness in the TA division, particularly in macro-sensitive polymer and materials testing applications [10][11] - China grew high single digits, with strong performance across all end markets, particularly in pharma and CDMO segments [20][76] Company Strategy and Development Direction - The company is focused on three strategic pillars: commercial execution, revitalizing innovation, and capturing long-term growth in high-growth adjacencies [12][15] - The pending combination with BD's biosciences and diagnostic solutions business is expected to accelerate entry into high-growth adjacencies and enhance the company's growth trajectory [27][28] - The company is raising its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and non-GAAP EPS guidance to $12.95 to $13.05 [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of the core business and the positive impact of the upcoming combination with BD [27][28] - The company anticipates a gradual return to growth for BD's biosciences and diagnostics solutions business, with expected growth rates improving in the coming years [31][32] - Management remains cautious about the impact of tariffs and macroeconomic conditions on certain segments, particularly in the TA division [10][71] Other Important Information - The company expects to deliver $345 million in adjusted EBITDA synergies by year five from the combination with BD, with $200 million in cost synergies and $290 million in revenue synergies [34][39] - The microbiology business from BD is seen as a strategic fit with significant value creation opportunities, particularly in infectious disease diagnostics [46][49] Q&A Session Summary Question: Can you provide an update on the replacement cycle in LC and competitive dynamics? - Management noted that the LCMS segment continues to grow high single digits, with strong replacement activity among large pharma customers and increasing growth in the CDMO customer base [57][58] Question: What is the timeline for bringing new products to market in microbiology? - Management indicated that it would take approximately three to five years to fully realize the opportunities in microbiology, with potential product introductions in two to three years [63][64] Question: How sustainable is the growth in China? - Management reported double-digit growth in China, driven by strong performance across all end markets, and remains cautiously optimistic for the back half of the year [76][78] Question: What are the drivers behind the operating margin being lighter than expected? - Management explained that the margin impact was primarily due to geographical mix and tariff remediation costs, with expectations for progressive improvement in margins in the second half of the year [82][84] Question: Can you elaborate on the $8 million sales pull forward? - Management expressed confidence in the $8 million figure based on order patterns and customer discussions, indicating it may impact both Q3 and Q4 [85][86]

Q2 2025 Financial Performance - Revenue decreased by $3.3 million, a -0.4% decline[7] - Organic revenue declined by -7.0%, with BSI down -7.2% and BEST down -4.8%[7] - Non-GAAP EPS was $0.32, a decrease of -38.5%, including a $0.06 FX headwind[7, 39] - Non-GAAP operating margin decreased to 9.0%, down -480 bps[7] H1 2025 Financial Performance - Revenue increased by $76.4 million, a 5.0% increase[9] - Organic revenue declined by -2.3%, with BSI down -1.4% and BEST down -11.5%[9] - Acquisition contributed +6.5% to revenue[9] - Non-GAAP EPS was $0.78, a decrease of -25.7%, including a $0.08 FX headwind[9, 42] - Non-GAAP operating margin decreased to 10.9%, down -300 bps[9] FY 2025 Outlook - Revenue is projected to be between $3.43 billion and $3.50 billion, representing a growth of +2% to +4%[48] - Organic revenue is expected to decline by -2% to -4%[48] - M&A is expected to contribute approximately +3.5% to revenue[48] - Non-GAAP EPS is projected to be between $1.95 and $2.05, a decline of -15% to -19%[48]